Neurotransmitter imbalances have been associated with many conditions, including Depression, Anxiety, Insomnia, Migraines, Fibromyalgia and other chronic pain syndromes and obesity. Restoring proper neurotransmitter balance is essential to managing and overcoming these conditions. Most people that have these signs of neurotransmitter imbalance are serotonin dominant – which means they will require proportionately more serotonin precursors than catecholamine (i.e., dopamine, norepinephrine and epinephrine) precursors to achieve optimal neurotransmitter function. There are only two disorders – Parkinson’s Disease and Restless Leg Syndrome – that are definitively dopamine dominant, although a small percentage (about 6-12%) of those with other disorders may also be dopamine dominant.
For those that are serotonin dominant, there is a typical progression to getting started with amino acid therapy. Usually, a person will begin taking two formulas – NeuroReplete and CysReplete – on a set daily schedule for 7 days without missing a dose. If symptoms remain after those 7 days (which occurs over 70% of the time) a specialized urine test is submitted to determine how to customize each person’s amino acid dosing. The following is a typical adult starting dose using NeuroReplete (NR) and CysReplete (CR), although the exact amount used can vary based on needs:
|NOON||4 PM||7 PM|
|4 NR||—||4 NR||
|2 CR||2 CR||
Most people find that taking the amino acids with food to be easiest; it also minimizes the probability of gastrointestinal upset.
Once the urine test results are received, your health care provider can begin to tailor your amino acid dosing to your specific needs. It usually takes 2-6 urine tests to optimize a person’s neurotransmitter levels.
Working with a provider that is skilled in the use of amino acid therapy can dramatically improve your results; to find if there is a provider near you, please contact NeuroResearch at 877-626-2220. If there is not a provider near you, please contact us – we’ll be happy to assist you.